DEPECA-1 – DEfeating PEnile CAncer 1 – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for advanced and metastatic penile carcinoma
Laufzeit: 01.01.2025 - 31.12.2029
imported
Kurzfassung
To evaluate the efficacy of combination of enfortumab vedotin plus avelumab in patients with locally advanced or metastatic penile squamous cell carcinoma (PeCa).
